Phenytoin in IgA nephropathy: a long-term controlled trial

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Immunoglobulin A (IgA) nephropathy is a chronic kidney disease characterized by immune complex deposition.
• Understanding the efficacy of therapeutic interventions on clinical and immunological aspects is crucial for patient management.

Purpose of the Study:

• To evaluate the long-term effects of phenytoin therapy on clinical and immunological parameters in patients with IgA nephropathy.
• To assess the impact of phenytoin on the progression of renal lesions and overall renal function.

Main Methods:

• A long-term nonrandomized controlled trial comparing phenytoin-treated (41 patients) and untreated (32 patients) IgA nephropathy groups.
• Follow-up duration averaged 17 months for the treated group and 14 months for the control group.
• Assessment of macroscopic and microscopic hematuria, renal function, serum IgA levels, polymeric IgA, and IgA immune complexes.

Main Results:

• Phenytoin significantly reduced episodes of macroscopic hematuria and diminished microhematuria.
• Serum IgA levels and polymeric IgA normalized in the treated group, with a decrease in IgA immune complexes.
• Despite immunological improvements, some patients in the treated group showed progression of glomerular and interstitial lesions.

Conclusions:

• Phenytoin can decrease clinical activity and correct some immunological alterations in IgA nephropathy patients.
• The drug demonstrated no significant beneficial effect on the progression of renal lesions.
• Results do not support phenytoin use in IgA nephropathy patients with normal renal function, highlighting potential non-immunological mechanisms in disease progression.